

CITATION REPORT

List of articles citing

Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease

DOI: 10.1111/1759-7714.12759
Thoracic Cancer, 2018, 9, 847-855.

Source: <https://exaly.com/paper-pdf/71064555/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
83	Nivolumab. <i>Reactions Weekly</i> , 2018 , 1713, 268-268	0	
82	Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. <i>Cancer Management and Research</i> , 2018 , 10, 7013-7019	3.6	7
81	Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 1798-1804	3.2	16
80	Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer. <i>Respiratory Investigation</i> , 2019 , 57, 451-459	3.4	35
79	High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019 , 10, 2006-2012	3.2	29
78	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 200, e31-e43	10.2	48
77	Highlights of thoracic oncology from the 2018 ERS International Congress. <i>ERJ Open Research</i> , 2019 , 5,	3.5	
76	The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 561-568	3.5	30
75	Immune checkpoint inhibitor use in antisynthetase syndrome. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019 , 15, 266-269	1.9	4
74	Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer. <i>European Respiratory Review</i> , 2019 , 28,	9.8	48
73	Managing Lung Cancer with Comorbid Interstitial Pneumonia. <i>Internal Medicine</i> , 2020 , 59, 163-167	1.1	7
72	Characterization of tumour mutation burden in patients with non-small cell lung cancer and interstitial lung disease. <i>Respirology</i> , 2020 , 25, 850-854	3.6	5
71	The utility of ground-glass attenuation score for anticancer treatment-related acute exacerbation of interstitial lung disease among lung cancer patients with interstitial lung disease. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 282-291	4.2	8
70	Tumour mutation burden of non-small cell lung cancer with pre-existing ILD. <i>Respirology</i> , 2020 , 25, 784-786	3.6	5
69	Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2020 , 69, 15-22	7.4	25
68	Tumor invasion in the central airway is a risk factor for early-onset checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 3576-3584	3.2	2
67	Case of Merkel cell carcinoma in a patient with pre-existing ILD. 2020 , 8,		0

66	Characteristics of non-small-cell lung cancer with interstitial pneumonia: variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia. <i>BMC Pulmonary Medicine</i> , 2020 , 20, 307	3.5	1
65	Immune Checkpoint Inhibitor-Related Pneumonitis. <i>Respiration</i> , 2020 , 99, 932-942	3.7	9
64	Existence-ils des contre-indications à l'immunothérapie dans les cancers broncho-pulmonaires ?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020 , 12, 2S373-2S377	0	
63	Clinical burden of immune checkpoint inhibitor-induced pneumonitis. <i>Respiratory Investigation</i> , 2020 , 58, 305-319	3.4	6
62	A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. <i>Oncologist</i> , 2020 , 25, e1589-e1592	5.7	0
61	Pulmonary toxicity of systemic lung cancer therapy. <i>Respirology</i> , 2020 , 25 Suppl 2, 72-79	3.6	8
60	Programmed cell death 1 (PD-1)/PD-ligand 1(PD-L1) inhibitors-related pneumonitis in patients with advanced non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020 , 16, 299-304	1.9	4
59	Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey. <i>Cancer Control</i> , 2020 , 27, 1073274820977200	2.2	2
58	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	45
57	Pembrolizumab for Previously Untreated Patients with Advanced Non-small-cell Lung Cancer and Preexisting Interstitial Lung Disease. <i>Internal Medicine</i> , 2020 , 59, 1939-1945	1.1	2
56	Anti-PD-1-Related Exacerbation of Interstitial Lung Disease in a Patient with Non-Small Cell Lung Cancer: A Case Presentation and Review of the Literature. <i>Cancer Investigation</i> , 2020 , 38, 365-371	2.1	6
55	Interstitial Lung Disease Associated with Lung Cancer: A Case-Control Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
54	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020 , 21, e435-e444	4.9	21
53	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. <i>Cancer Medicine</i> , 2020 , 9, 2352-2362	4.8	14
52	Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer. <i>Thoracic Cancer</i> , 2020 , 11, 1052-1060	3.2	22
51	Efficacy and tolerance of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung disease - Reply. <i>Respirology</i> , 2020 , 25, 892-893	3.6	2
50	Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2021 , 12, 153-164	3.2	10
49	PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research. <i>Technology in Cancer Research and Treatment</i> , 2021 , 20, 15330338211004942	2.7	49

48	Preexisting autoimmune disease and immune-related adverse events associated with anti-PD-1 cancer immunotherapy: a national case series from the Canadian Research Group of Rheumatology in Immuno-Oncology. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 2197-2207	7.4	7
47	COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report. 2021 , 9,		5
46	Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. <i>European Journal of Cancer</i> , 2021 , 145, 179-182	7.5	5
45	Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 537-547	4.1	2
44	Management and Prognosis of Interstitial Lung Disease With Lung Cancer (ILD-LC): A Real-World Cohort From Three Medical Centers in China. <i>Frontiers in Molecular Biosciences</i> , 2021 , 8, 660800	5.6	1
43	Pembrolizumab Induced Acute Persistent Airway Disease in a Patient with Recurrent Respiratory Papillomatosis (RRP). <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2021 , 34894211021276	2.1	1
42	Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease. <i>Lung Cancer</i> , 2021 , 155, 120-126	5.9	7
41	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. <i>Frontiers in Immunology</i> , 2021 , 12, 663986	8.4	6
40	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021 , 10, 2752-2765	4.4	1
39	Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , 2021 , 11, 12732	4.9	3
38	Peripheral Blood Biomarkers for Early Diagnosis, Severity, and Prognosis of Checkpoint Inhibitor-Related Pneumonitis in Patients With Lung Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 698832	5.3	3
37	Current Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Interstitial Pneumonia. <i>Cancers</i> , 2021 , 13,	6.6	2
36	Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina. <i>Chest</i> , 2021 , 160, 731-742	5.3	15
35	Immunotherapy and Stereotactic Ablative Radiotherapy for Lung Cancer with Co-existing Interstitial Lung Disease: A Case Report. <i>Clinical Lung Cancer</i> , 2021 , 22, e734-e737	4.9	
34	Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers. <i>JAMA Network Open</i> , 2020 , 3, e2022906	10.4	13
33	The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. <i>Cancer Biology and Medicine</i> , 2020 , 17, 599-611	5.2	10
32	Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 1	3.5	2
31	Toxicité pulmonaires des immunothérapies : évaluer et traiter. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019 , 11, S491-S501	0	

30	Treatment Strategy for Advanced Non-small-cell Lung Cancer with Interstitial Lung Disease. <i>Japanese Journal of Lung Cancer</i> , 2020 , 60, 74-80	0.1	
29	Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach. <i>Clinical Pulmonary Medicine</i> , 2020 , 27, 183-192	0.3	
28	[A Review of Drug Therapy of Lung Cancer with Interstitial Lung Disease]. <i>Chinese Journal of Lung Cancer</i> , 2020 , 23, 286-293	0.6	
27	Pulmonary Toxicities of Immunotherapy.. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1342, 357-375	3.6	
26	Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients with Advanced Non-Small Cell Lung Cancer and Pre-existing Interstitial Lung Diseases: A Systematic Review and Meta-Analysis.. <i>Chest</i> , 2022 ,	5.3	1
25	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review.. <i>Human Vaccines and Immunotherapeutics</i> , 2022 , 1-12	4.4	1
24	Rate and risk factors of recurrent immune checkpoint inhibitor-related pneumonitis in patients with lung cancer.. <i>Translational Lung Cancer Research</i> , 2022 , 11, 381-392	4.4	0
23	Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.. <i>BMC Cancer</i> , 2022 , 22, 364	4.8	0
22	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism.. <i>Frontiers in Immunology</i> , 2022 , 13, 830631	8.4	3
21	Association of pre-existing lung interstitial changes with immune-related pneumonitis in patients with non-small lung cancer receiving immunotherapy.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	1
20	Lung cancer in patients with fibrosing interstitial lung diseases □An overview of current knowledge and challenges. <i>ERJ Open Research</i> , 00115-2022	3.5	1
19	Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.. <i>BMC Cancer</i> , 2022 , 22, 551	4.8	0
18	Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.. <i>Frontiers in Immunology</i> , 2022 , 13, 779691	8.4	8
17	Impact of PD1 and PDL1 immunotherapy on non-small cell lung cancer outcomes: a systematic review. <i>Thorax</i> , thoraxjnl-2020-215614	7.3	0
16	Response. <i>Chest</i> , 2022 , 162, e66-e67	5.3	
15	Pulmonary adverse events following immune checkpoint inhibitors. <i>Current Opinion in Pulmonary Medicine</i> , Publish Ahead of Print,	3	0
14	Immune-Checkpoint-Inhibitor-Related Lung Toxicity: A Multicentre Real-Life Retrospective Portrait from Six Italian Centres. 2022 , 12, 1149		0
13	Clinical Significance of Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor- Induced Interstitial Lung Disease in Patients with Non-Small Cell Lung Cancer.		

12	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
11	Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.	0
10	Imaging of Drug-Related Pneumonitis in Oncology.	0
9	Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.	0
8	Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer.	0
7	Idiopathic pulmonary fibrosis: the risk of cancer and the impact on cancer care. 2022, 134-144	0
6	Management of Lung Cancer in the Patient with Interstitial Lung Disease.	0
5	Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysis. 2022, 18,	2
4	Metabolic landscape dysregulation in bronchoalveolar lavage fluid of checkpoint inhibitor pneumonitis. 2023, 109230	0
3	Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.	0
2	Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment. 2023, 19, 259-270	0
1	Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience.	0